Febrile 107: A Quick PIP Talk
12 snips
Jul 29, 2024 Maxime Billick, a recent ID staff graduate set to pursue a Master of Public Health at Harvard, and Isaac Bogoch, an infectious diseases physician at the University of Toronto, dive deep into innovative HIV prevention strategies. They explore the buffet of options available, focusing on PrEP, PEP, and the emerging PIP strategy. The conversation addresses the nuances of personalized risk assessment and the importance of tailored strategies for at-risk populations, especially young men. Their insights shed light on the evolving landscape of HIV prevention.
AI Snips
Chapters
Transcript
Episode notes
Biomedical HIV Prevention
- Biomedical HIV prevention uses medicine to prevent HIV acquisition.
- Options include PrEP (daily pills or injectables), on-demand PrEP, and PEP (post-exposure).
PrEP Barriers
- PrEP works well but faces barriers like cost, daily pill adherence, and potential side effects.
- The 2-1 regimen is only proven for men who have sex with men, and its efficacy for infrequent encounters is uncertain.
PEP Barriers
- Traditional PEP is highly effective but has implementation challenges.
- Barriers include recognizing exposure, accessing care, awareness, clinician knowledge, cost, and discomfort discussing sensitive situations.